THE abnormal protein-bound polysaccharide associated with multiple myeloma (Sachs, Cady and Ross, 1954) and the handling of radiosulfate by patients with this disorder (Siegel, Sachs and Graig, 1959) have been reported previously. The present study describes the fate of 35S labelled cystine in myeloma anid other malignant neoplasms, and compares these results with those published earlier for radiosulfate.
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MATERIALS AND METHODS
35S as 1-cystine (specific activity of about 30 mc/g.) in doses of approximately 0* 5 mc was administered intravenously to 5 patients with multiple myeloma and to 5 patients with other neoplastic diseases ( Table I ). The assays of radioactivity were performed with a gas flow counter, since 35S is a pure, weak beta emitter (0.168 mev maximum energy; 87 days half-life). Appropriate corrections for self-absorption and back-scattering were made for the specimen geometry employed as well as for physical decay. The detectors used were calibrated against 35S standard solutions furnished by the National Bureau of Standards. Blood was collected by venipuncture at intervals of 5 minutes, 1 hour, 4 hours, 8 hours, 24 hours, 2 days, 3 days, 5 days, 7 days, and 14 days following administration of the tagged cystine. Blood specimens (about 15 ml.) were placed in test tubes containing two drops of versene to prevent coagulation. Urine was collected for the first 8 hours, the next 16 hours, and daily thereafter for two weeks after injection of 35S cystine.
Calculations. -The 35S concentration (per cent dose/liter) in whole blood and plasma ( Fig. 1 ) and the fraction of the 35S dose excreted (per cent dose excreted) in urine during 14 days following administration of the radioisotope were computed (Table I and Fig. 2 ). The apparent space of dilution was calculated from these blood and plasma data. This computation inivolved finding the hypothetical concentration at zero-time by means of graphical extrapolation in order to obtain the so-called zero-time radiosulfate space (Ryan et al., 1956 ). The ratios of space to body weight and body surface were determined. Body surface of eachl subject was obtained from the patient's weight and height using the conventionial Duii Bois relationship.
RESULTS
35S blood levels. 35S in whole blood, as well as in plasma, falls rapidly for the first 8 hours and then declines slowly (Fig. 1) . This pattern is found in both multiple myeloma patients and the othel subjects. Since the levels and patterniis are almost identical in whole blood and in plasma, only whole blood data are given in Fig. 1 By graphing the logarithm of whole blood and plasma 35S concentration against time, it was found that the curves thus obtained could be resolved into exponential components. The curves from three of five multiple myeloma patients have two decay rates. An initial rapid decrease, corresponding to a half-disappearance time (T1) of about 0-45 hour characterizes the fall of 35S during the first hour. The decline thereafter is quite slow, described by a half-disappearance time (T3) of about 280 hours (Fig. 2 ). An intermediate half-time (T2) of about 2.5 hours, however, was present for the other two myeloma patients during the 1 to 8 hour interval following the injection of the doses. For the other group of patients, three distinct rates governed the disappearance of the 35S (Fig. 3 ). An initial halftime (T1) of about 0.26 hour for the first hour is followed for the next 8 hours by an intermediate component (T2) of about 1.4 hours. For the ensuing period, the gradual fall is described by a half-time (T3) of about 160 hours. Mean values of these half-disappearance times for both groups of patients, as derived from their respective whole blood and plasma curves, based on the data collected over a two week period, are listed in Table II . The figures reproduced here ( Fig. 1 and 2 (Fig. 4) By the end of the first week, about 30 per cent of the dose has been excreted.
35S-cystine spaces of dilution. The zero-time radiosulfate whole blood spaces and their respective ratios to body surface and to weight are given in Table I. These results are similar for both the myeloma patients and those having other neoplasms. The average space for patients with myeloma is 7.39 ± 1.41 liters, corresponding to 13.2 ± 3.49 x 10-2 liter per kilogram of body weight. For the other patients, an average space of 8.66 i 2.67 liters or 14.7 ± 4.04 x 10-2 liter per kilogram of body weight was found. As was noted earlier, since the 35S concentration in the whole blood and plasma are almost identical, the respective spaces are likewise very similar, and, for brevity, only the whole blood radiosulfate spaces are tabulated.
DISCUSSION
The intravenous administration of 35S-1-cystine provides an immediate supply of this readily detected labeled amino acid to all sites of protein synthesis. The 35S labeled cystine exchanges its labeled position with the other amino acids only slightly, if at all. The sulfur of 35S-cystine is not transferred to methionine. It is believed that through the use of this amino acid the uptake and loss of isotope by the protein are almost exclusively in the form of the administered amino acid (Goldsworthy and Volwiler, 1957) . The resulting turnover curve is usually divided into the following phases (Armstrong, Bronsky and Hershman, 1955; Golds- worthy and Volwiler, 1957): (a) rapid incorporation of the amino acid radioactivity into the protein and rapid release of the newly synthesized protein into the circulation in the first 24 hours; (b) the distribution and mixing period, lasting a few days; (c) the exponential portion of the curve, presumed to reflect primarily the rate of metabolic degradation of the labeled protein; and (d), if the experiment continues for sufficient time, a phase reflecting the re-incorporation of the isotope into the protein.
In comparing the fate of tagged cystine with that of radiosulfate, some significant differences are observed. While the spaces of dilution for these two substances are quite similar and in accord with those reported for radiosulfate for normal subjects as well as for others having malignancies (Siegel et al., 1959; Ryan et al., 1956; Walser, Seldin and Grollman, 1953) , the handling and turnover of these compounds are quite different. Fig. 1 illustrates the 35S whole blood concentration as a function of time for those receiving labeled cystine. Following administration of labeled cystine the 35S blood concentration decreases slowly; thus, by the second day, when the 35S concentration following radiosulfate, as previously reported by us, is less than 0.5 per cent dose/liter, the 35S concentration from cystine is about six times greater. This markedly slow fall in 35S blood levels is characterized by the greatly prolonged late (T3) half-disappearance times following labeled cystine (Table II) as compared to those found for radiosulfate. Thus, the average value T3 for patients with myeloma given 35S-cystine is 281 hours as compared to 15-9 hours following tagged sulfate. A similar lengthening of this parameter is observed also for the patients with other neoplasms. There is a corresponding lower output of 35S in the urine from 35S-cystine as compared to that following administration of radiosulfate (Fig. 4) . By the second day, when more than 60 per cent of the injected sulfate has been excreted, those given 35S-cystine have excreted only about 20 per cent of the dose. Furthermore, for those given labeled cystine, an equilibrium is attained after the second day, the cumulative urinary output growing exponentially, with an average doubling-time, as noted earlier, of about 173 hours, which is in good agreement with the observed late half-disappearance times (Table II) . Thus, after the second day, the constant fraction of the remaining dose, which disappears daily from the blood, was found in the urine, suggesting that the 35S is then being degraded and directly excreted.
When 35S-cystine is administered to control subjects, the label is incorporated into the normal serum albumin and globulins. When 35S-cystine is given to patients with myeloma, the label also is incorporated into the normal albumin and globulins as well as the abnormal myeloma globulins. The present investigation did not inivolve study of homologous serum proteins, and the curves obtained represent summation effects for all the serum protein complexes. It is possible that if individual globulins were studied, greater differences might have been observed between the turnover of the 35S-cystine labeled normal globulins and the labeled myeloma globulins (Putnam, 1959) .
There is a suggestive finding of a difference in the fate of 35S-cystine for myeloma patients as compared to those having other malignancies. The initial (T1) and late (T3) half-disappearance times are longer for those having myeloma (Table II) . This suggests that the hyperglobulinemia of myeloma may result from a slower catabolism of myeloma globulin. In this connection, Putnam and Hardy (1955) observed a greater half-disappearance time for the turnover of beta myeloma globulin than that obtained for the normal beta globulins by London (1950) , and stated that the hyperglobulinemia of myeloma might be due to accumulation of the myeloma globulin by virtue of its slow turnover rate. SUMMARY 35S-l-cystine (specific activity 30 mc/g.) in doses of approximately 0.5 mc was administered intravenously to five patients with multiple myeloma and to five subjects with other neoplastic diseases. For both groups of patients, the 35S concentration of whole blood and plasma were similar. The 35S blood levels declined slowly; at five days after administration of the dose they were approximately three-quarters of the initial 8 hour values. The mean zero-time spaces of dilution were 7.39 ± 1.41 liters for the patients with multiple myeloma and 8-66 ± 2.67 liters for those with other neoplasms. 35S urinary excretion was low, 13.6 to per cent of the dose appearing in the urine within 72 hours. The turnover and excretion of 35S administered as cystine are very much slower than when given as radiosulfate. By graphical analysis, it was possible to resolve the blood concentration curves into three exponential components. Patients with multiple myeloma were found to have longer initial and late half-disappearance times when compared to the subjects with other neoplastic diseases.
